Unnamed: 0,title,date,stock,sentiment
42353.0,"The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates",2020-06-09 07:46:00-04:00,AGIO,negative
42354.0,Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia,2020-06-08 16:02:00-04:00,AGIO,positive
42355.0,"The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage",2020-06-07 13:43:00-04:00,AGIO,neutral
42356.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,AGIO,positive
42357.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2020-05-24 14:40:00-04:00,AGIO,neutral
42358.0,Agios Highlights Publication Of TIBSOVO Phase 3 Data In The Lancet Oncology Demonstrating 'Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients',2020-05-19 07:08:00-04:00,AGIO,positive
42359.0,Agios Pharma To Present Updated Clinical Proof-Of-Concept Data From Phase 2 Study Of Mitapivat In Thalassemia At European Hematology Association Jun. 12,2020-05-14 09:43:00-04:00,AGIO,neutral
42360.0,Agios Pharma To Present Updated Data From Phase 1 Study Of Vorasidenib In Non-Enhancing Glioma At ASCO May 29,2020-05-13 17:27:00-04:00,AGIO,neutral
42361.0,"JP Morgan Maintains Overweight on Agios Pharmaceuticals, Raises Price Target to $82",2020-05-04 09:25:00-04:00,AGIO,neutral
42362.0,"Agios Pharma S-3 Shows Registration For Mixed Securities Shelf Offering, No Size Disclosed",2020-04-30 16:28:00-04:00,AGIO,neutral
42363.0,Agios Reiterates 2020 TIBSOVO Net US Revenue Guidance Of $105M–$115M,2020-04-30 07:21:00-04:00,AGIO,neutral
42364.0,"Agios Pharmaceuticals Q1 EPS $(0.590) Beats $(1.670) Estimate, Sales $87.098M May Not Compare To $30.830M Estimate",2020-04-30 07:20:00-04:00,AGIO,neutral
42365.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,AGIO,positive
42366.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,AGIO,negative
42367.0,Agios Announces The European Medicines Agency Committee For Orphan Medicinal Products Issued A Positive Opinion On The Company's Application For Orphan Drug Designation For Its Investigational Medicine Mitapivat As A Potential Treatment For Pyruvate Kinase,2020-03-30 16:06:00-04:00,AGIO,positive
42368.0,Agios Says AG-270 Phase 1 Combo Expansion Trials Ongoing,2020-03-25 16:04:00-04:00,AGIO,neutral
42369.0,Agios Says Research Term Of Metabolic Immuno-Oncology Collaboration Will Conclude At End Of Initial 4-Year Period In May '20,2020-03-25 16:03:00-04:00,AGIO,neutral
42370.0,Agios Pharma Reports Celgene Declines To Exercise Opt-In Right For AG-270,2020-03-25 16:03:00-04:00,AGIO,neutral
42371.0,"Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a PKR Activator",2020-03-23 07:02:00-04:00,AGIO,neutral
42372.0,"Benzinga's Top Upgrades, Downgrades For March 4, 2020",2020-03-04 10:08:00-05:00,AGIO,positive
42373.0,"Barclays Initiates Coverage On Agios Pharmaceuticals with Equal-Weight Rating, Announces $50 Price Target",2020-03-04 05:34:00-05:00,AGIO,neutral
42374.0,"Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticals, Raises Price Target to $70",2020-02-14 06:59:00-05:00,AGIO,negative
42375.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,AGIO,negative
42376.0,"Agios Pharmaceuticals Q4 EPS $(1.6) Beats $(1.72) Estimate, Sales $35.44M Beat $33.72M Estimate",2020-02-13 07:37:00-05:00,AGIO,neutral
42377.0,The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight,2020-02-09 15:22:00-05:00,AGIO,neutral
42378.0,"Agios Says In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in Clinical Development and a Broad Research Pipeline –",2020-01-12 16:29:00-05:00,AGIO,neutral
42379.0,Agios Pharma Shares Tick Higher On Spike In Volume As Traders Circulate Article From Spain's Okdiario 'Grifols puts 1.5 billion on the table to buy 50% of Agios',2020-01-09 12:08:00-05:00,AGIO,positive
42380.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,AGIO,positive
42381.0,30 Stocks Moving in Tuesday's Pre-Market Session,2019-12-17 07:25:00-05:00,AGIO,neutral
42382.0,5 Stocks Moving In Monday's After-Hours Session,2019-12-16 17:48:00-05:00,AGIO,neutral
42383.0,Agios Pharma shares are trading higher after the company was granted Breakthrough Therapy designation from the FDA for TIBSOVO for the treatment of adult patients with relapsed or refractory MDS with an IDH1 mutation.,2019-12-16 16:05:00-05:00,AGIO,positive
42384.0,Agios Pharma Reports FDA Breakthrough Therapy Designation For TIBSOVO For Treatment Of Adult Patients With Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation,2019-12-16 16:00:00-05:00,AGIO,neutral
42385.0,Agios Pharma Offers Updated Data From Mitapivat From Extension Phase Of DRIVE PK Study In Patients With Pyruvate Kinase Deficiency,2019-12-09 10:06:00-05:00,AGIO,neutral
42386.0,"BMO Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $49",2019-12-09 09:44:00-05:00,AGIO,neutral
42387.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,AGIO,neutral
42388.0,Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results at ASH 2019,2019-12-08 09:15:00-05:00,AGIO,neutral
42389.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,AGIO,positive
42390.0,"JP Morgan Maintains Overweight on Agios Pharmaceuticals, Lowers Price Target to $68",2019-12-04 08:24:00-05:00,AGIO,negative
42391.0,Agios Pharmaceuticals Option Alert: Jan 17 $40 Calls Sweep (2) near the Ask: 500 @ $3.201 vs 55 OI; Ref=$39.17,2019-11-27 15:21:00-05:00,AGIO,positive
42392.0,"Benzinga's Top Upgrades, Downgrades For November 26, 2019",2019-11-26 09:59:00-05:00,AGIO,positive
42393.0,"Cantor Fitzgerald Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces $64 Price Target",2019-11-26 06:02:00-05:00,AGIO,negative
42394.0,Agios Highlights Presentation New Pharmacodynamic And Response Data From Both Cohorts Of Perioperative Study Of Vorasidenib And TIBSOVO In Patients With IDH1 Mutant Positive Low-Grade Glioma,2019-11-22 16:03:00-05:00,AGIO,positive
42395.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,AGIO,positive
42396.0,The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down,2019-11-17 08:42:00-05:00,AGIO,neutral
42397.0,10 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-08 07:48:00-05:00,AGIO,neutral
42398.0,30 Stocks Moving in Friday's Pre-Market Session,2019-11-08 07:21:00-05:00,AGIO,neutral
42399.0,Agios Prices 8.25M Share Public Offering of Common Stock @$31/Share,2019-11-08 04:18:00-05:00,AGIO,positive
42400.0,30 Stocks Moving in Thursday's Pre-Market Session,2019-11-07 07:58:00-05:00,AGIO,neutral
42401.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,AGIO,negative
42402.0,"14 Stocks To Watch For November 7, 2019",2019-11-07 04:29:00-05:00,AGIO,neutral
42403.0,Agios Announes 7.5M Share Common Stock Offering,2019-11-06 16:16:00-05:00,AGIO,positive
42404.0,"Citigroup Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $64",2019-11-05 07:38:00-05:00,AGIO,negative
42405.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,AGIO,neutral
42406.0,"Agios Pharmaceuticals Earlier Reported Q3 EPS $(1.81) Misses $(1.8) Estimate, Sales $26.024M Miss $32.99M Estimate",2019-10-31 09:17:00-04:00,AGIO,negative
42407.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,AGIO,positive
42408.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,AGIO,neutral
42409.0,"Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors",2019-10-27 11:52:00-04:00,AGIO,negative
42410.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,AGIO,neutral
42411.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-09 12:55:00-04:00,AGIO,negative
42412.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,AGIO,negative
42413.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,AGIO,negative
42414.0,Agios Pharma Reports Data From Phase 3 ClarIDHy Trial Of TIBSOVO Showed Significant Improvement In Progression-Free Survival Compared To Placebo,2019-09-30 10:32:00-04:00,AGIO,positive
42415.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,AGIO,positive
42416.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,AGIO,neutral
42417.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,AGIO,negative
42418.0,"Benzinga's Top Upgrades, Downgrades For September 23, 2019",2019-09-23 12:47:00-04:00,AGIO,positive
42419.0,Guggenheim Upgrades Agios Pharmaceuticals to Buy,2019-09-23 06:21:00-04:00,AGIO,neutral
42420.0,"Benzinga's Top Upgrades, Downgrades For September 12, 2019",2019-09-12 09:32:00-04:00,AGIO,positive
42421.0,"BMO Capital Initiates Coverage On Agios Pharmaceuticals with Outperform Rating, Announces $45 Price Target",2019-09-12 07:19:00-04:00,AGIO,neutral
42422.0,"The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris",2019-09-10 07:36:00-04:00,AGIO,neutral
42423.0,Agios Highlights Publication Of Data For Mitapivat From Core And Extension Phases Of DRIVE PK Study In Patients With Pyruvate Kinase Deficiency In The New England Journal Of Medicine,2019-09-04 17:01:00-04:00,AGIO,neutral
42424.0,Stocks That Hit 52-Week Lows On Wednesday,2019-09-04 11:39:00-04:00,AGIO,negative
42425.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,AGIO,positive
42426.0,"The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings",2019-08-29 07:38:00-04:00,AGIO,negative
42427.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,AGIO,positive
42428.0,Alamos Gold Option Alert: Mar 20 $10 Calls Sweep (15) near the Ask: 500 @ $0.5 vs 174 OI; Ref=$7.54,2019-08-06 10:24:00-04:00,AGIO,positive
42429.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,AGIO,positive
42430.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,AGIO,negative
42431.0,"Agios Pharmaceuticals Q2 EPS $(1.87) Misses $(1.7) Estimate, Sales $26.221M Miss $27.05M Estimate",2019-08-01 07:23:00-04:00,AGIO,negative
42432.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,AGIO,negative
42433.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,AGIO,positive
42434.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,AGIO,positive
42435.0,Agios Reports Presented Updated Data From Phase 1 Studies Of TIBSOVO In Newly-Diagnosed Adult Patients With IDH1 Mutant Acute Myeloid Leukemia Not Eligible For Intensive Chem,2019-06-03 08:02:00-04:00,AGIO,neutral
42436.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,AGIO,neutral
42437.0,"Goldman Sachs Assumes Agios Pharmaceuticals, Inc. - Common Stock at Neutral, Announces Price Target $55",2019-05-23 08:50:00-04:00,AGIO,neutral
42438.0,63 Biggest Movers From Yesterday,2019-05-17 05:05:00-04:00,AGIO,neutral
42439.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-05-16 12:36:00-04:00,AGIO,neutral
42440.0,Agios Pharmaceuticals shares are trading higher after the company achieved its primary endpoint for the Phase 3 ClarlDHy trial of TIBSOVO.,2019-05-16 11:30:00-04:00,AGIO,positive
42441.0,30 Stocks Moving In Thursday's Pre-Market Session,2019-05-16 08:12:00-04:00,AGIO,neutral
42442.0,"The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics",2019-05-16 07:40:00-04:00,AGIO,neutral
42443.0,6 Stocks Moving In Wednesday's After-Hours Session,2019-05-15 17:02:00-04:00,AGIO,neutral
42444.0,Agios Pharmaceuticals shares are trading higher after the company reported its Phase 3 ClarlDHy Trial of TIBSOVO achieved its primary endpoint in previously treated IDH1 mutant Cholangiocarcinoma patients.,2019-05-15 16:11:00-04:00,AGIO,positive
42445.0,Agios Reports Randomized Phase 3 ClarIDHy Trial Of TIBSOVO Achieved Primary Endpoint In Previously-Treated IDH1 Mutant Cholangiocarcinoma Patients,2019-05-15 16:04:00-04:00,AGIO,neutral
42446.0,Agios Reports FDA Approval Of Supplemental New Drug Application For TIBSOVO As Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy,2019-05-02 13:19:00-04:00,AGIO,positive
42447.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,AGIO,positive
42448.0,"Agios Pharmaceuticals Q1 EPS $(1.59) Beats $(1.75) Estimate, Sales $30.227M Beat $22.69M Estimate",2019-05-02 08:11:00-04:00,AGIO,neutral
42449.0,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",2019-03-27 07:52:00-04:00,AGIO,positive
42450.0,Agios Pharma Reports Received FDA Breakthrough Therapy Designation For TIBSOVO In Combo With Azacitidine For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy,2019-03-26 16:01:00-04:00,AGIO,neutral
42451.0,Agios Pharma Gives an Update on its Phase 1 Study of Ivosidenib in Combination with Azacitidine,2019-02-25 07:20:00-05:00,AGIO,neutral
42452.0,Oppenheimer Earlier Assumed Agios Pharmaceuticals at Perform,2019-02-20 11:25:00-05:00,AGIO,neutral
42453.0,Agios Announces FDA Acceptance Of Supplemental New Drug Application For TIBSOVO For Treatment Of Patients With Newly Diagnosed Acute Myeloid Leukemia With An IDH1 Mutation Not Eligible For Standard Therapy,2019-02-20 07:07:00-05:00,AGIO,positive
42454.0,"Leerink Swann Upgrades Agios Pharmaceuticals to Outperform, Announces $80 Target",2019-02-15 09:35:00-05:00,AGIO,neutral
42455.0,"Agios Pharmaceuticals shares are trading higher after the company reported Q4 EPS of $(1.58), beating the $(1.62) estimate and sales of $30.013 million, beating the $22.04 million estimate.",2019-02-14 11:27:00-05:00,AGIO,negative
42456.0,"Agios Pharmaceuticals Earlier Reported Q4 EPS $(1.58) Beats $(1.62) Estimate, Sales $30.013M Beat $22.04M Estimate",2019-02-14 08:01:00-05:00,AGIO,neutral
42457.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,AGIO,neutral
42458.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,AGIO,negative
42459.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,AGIO,positive
42460.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,AGIO,negative
42461.0,56 Biggest Movers From Yesterday,2018-12-04 05:02:00-05:00,AGIO,neutral
42462.0,Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS),2018-12-03 10:32:00-05:00,AGIO,positive
42463.0,"Agios Pharma To Offer Updated Phase 1 Study Data Of Ivosidenib, Enasidenib In Combo With Standard Induction, Consolidation Chemotherapy In Newly-Diagnosed AML Patients With IDH Mutation",2018-12-03 10:19:00-05:00,AGIO,positive
42464.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,AGIO,neutral
42465.0,"Watching Celgene, Agio Pharma Shares Following Warning From FDA Symptoms Of Serious Condition Affecting Blood Cells Not Being Regonized With IDHIFA",2018-11-29 14:20:00-05:00,AGIO,negative
42466.0,Agios Pharma Offers Updated Data From Phase 1 Dose-Escalation Study Of AG-881 In Patients With IDH Mutant Positive Advanced Glioma: Median Treatment Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remaining,2018-11-16 07:06:00-05:00,AGIO,positive
42467.0,"Agios Pharmaceuticals Q3 EPS $(1.63) Misses $(1.62) Estimate, Sales $15.198M Miss $19.12M Estimate",2018-11-01 07:32:00-04:00,AGIO,negative
42468.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,AGIO,negative
42469.0,"Leerink Swann Initiates Coverage On Agios Pharmaceuticals with Market Perform Rating, Announces $80 Price Target",2018-09-25 08:49:00-04:00,AGIO,neutral
42470.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,AGIO,positive
42471.0,26 Stocks Moving In Wednesday's Pre-Market Session,2018-09-05 08:01:00-04:00,AGIO,neutral
42472.0,"Agios Pharmaceutials 8-K Shows On Sept 4, Co. And Celgene Agreed To Terminate Collaboration And License Deal",2018-09-05 06:50:00-04:00,AGIO,positive
42473.0,Agios Pharma Reports CEO David Schenkein To Transition To Role As Exec. Chair; Jackie Fouse Named Replacement As CEO,2018-09-04 17:58:00-04:00,AGIO,neutral
42474.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,AGIO,positive
42475.0,"Agios Pharmaceuticals Q2 EPS $(1.19) Beats $(1.55) Estimate, Sales $40.414M Beat $11.28M Estimate",2018-08-02 08:50:00-04:00,AGIO,neutral
42476.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,AGIO,neutral
42477.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-07-24 08:02:00-04:00,AGIO,neutral
42478.0,"Hearing Agios Prices Tibsovo At $26,115/Month",2018-07-20 12:32:00-04:00,AGIO,neutral
42479.0,FDA Says Agios Pharmaceutical' Tibsovo Prescribing Info Includes Boxed Warning That A Possibly Fatal Adverse Reaction Known As Differentiation Syndrome Can Occur,2018-07-20 11:32:00-04:00,AGIO,negative
42480.0,Agios Pharmaceuticals Reports FDA Grants Approval of TIBSOVO,2018-07-20 10:48:00-04:00,AGIO,positive
42481.0,Agios And CStone Pharmaceuticals Announce Exclusive Collaboration And License Agreement To Develop And Commercialize Ivosidenib In Greater China; Agios To Receive $12M Upfront Payment And Is Eligible For Up Tp $412M In Milestones,2018-06-26 08:06:00-04:00,AGIO,positive
42482.0,"Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street",2018-06-21 08:39:00-04:00,AGIO,neutral
42483.0,"Agios Pharmaceuticals Reports Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidin; Reports ORR of 78%, CR Rate of 44% and CR/CRi/CRp Rate of 65% in the Ivosidenib Arm; Molecular Clearance Observed in 7 Out of 21 Patients",2018-06-04 09:03:00-04:00,AGIO,neutral
42484.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,AGIO,negative
42485.0,Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO,2018-06-01 08:16:00-04:00,AGIO,neutral
42486.0,"Investors Should Own Agios For 'The Next Several Years,' Analyst Says",2018-05-31 16:04:00-04:00,AGIO,neutral
42487.0,"PiperJaffray Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces $125 Price Target",2018-05-31 08:11:00-04:00,AGIO,negative
42488.0,Citigroup Earlier Initiated Coverage On Agios Pharmaceuticals with Buy Rating,2018-05-23 10:35:00-04:00,AGIO,neutral
42489.0,13F From Cooperman's Omega Shows New Stake In Agios Pharma,2018-05-15 10:09:00-04:00,AGIO,neutral
42490.0,"Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down",2018-05-04 08:16:00-04:00,AGIO,neutral
42491.0,"Agios Pharmaceuticals Q1 EPS $(1.63), Inline, Sales $8.762M Miss $10.6M Estimate",2018-05-04 07:05:00-04:00,AGIO,negative
42492.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,AGIO,neutral
42493.0,7 Biggest Price Target Changes For Wednesday,2018-04-11 09:59:00-04:00,AGIO,neutral
42494.0,"Credit Suisse Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $95.00",2018-04-11 07:28:00-04:00,AGIO,positive
42495.0,Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion,2018-03-19 07:01:00-04:00,AGIO,positive
42496.0,"Agios Pharmaceuticals Reports FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib, PDUFA date set for August 21, 2018",2018-02-15 11:58:00-05:00,AGIO,positive
42497.0,"Credit Suisse Maintains Outperform on Agios Pharmaceuticals Inc, Raises price target to $80.00",2018-02-15 10:23:00-05:00,AGIO,positive
42498.0,"JP Morgan Maintains Overweight on Agios Pharmaceuticals Inc, Raises price target to $85.00",2018-02-15 09:59:00-05:00,AGIO,neutral
42499.0,Agios Shares Fall ~$2 Over Last Min. As Oppenheimer Downgrades To Perform,2018-02-14 14:00:00-05:00,AGIO,positive
42500.0,"Agios Reports Q4 EPS $(1.81) vs $(1.66) Est., Sales $9.79M vs $13.3M Est.",2018-02-14 07:08:00-05:00,AGIO,neutral
42501.0,"Agios Shares Up 5.87% At $72.30, Despite Announcing A 7.09M Share Common Stock Offering Priced at $67/Share",2018-01-19 11:41:00-05:00,AGIO,positive
42502.0,A Survey Of Celgene's M&A Strategy,2018-01-19 09:41:00-05:00,AGIO,neutral
42503.0,Agios Prices ~7.09M Share Public Offering of Common Stock @$67/Share,2018-01-19 03:58:00-05:00,AGIO,positive
42504.0,Agios Pharma Reports $400M Common Stock Offering,2018-01-17 16:01:00-05:00,AGIO,neutral
42505.0,Agios Pharma Shares Down ~1% Mon.; Co. Earlier Outlined Key '18 Priorities,2018-01-08 11:56:00-05:00,AGIO,positive
42506.0,"Agios Submits New Drug Application to the FDA for Ivosidenib, Announces FDA Clearance of an Investigational NDA for AG-270",2017-12-26 07:31:00-05:00,AGIO,neutral
42507.0,Oppenheimer Serves Up 29 Top Stock Ideas For January,2017-12-19 17:43:00-05:00,AGIO,positive
42508.0,"UPDATE: Agios Highlights 'In 125 R/R AML Patients From the Primary Analysis Set, Combined CR+CRh Rate of 30.4% with a Median Duration of 8.2 Months'",2017-12-11 16:01:00-05:00,AGIO,positive
42509.0,"Agios Pharma Offers First Expansion Data, Updated Dose-Escalation Data Supporting NDA Submission For IDH1m R/R AML By Year End '17",2017-12-11 16:01:00-05:00,AGIO,positive
42510.0,"Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency at #ASH2017",2017-12-11 04:02:00-05:00,AGIO,neutral
42511.0,Oppenheimer's Top Stock Picks For December,2017-11-30 10:17:00-05:00,AGIO,positive
42512.0,Agios Pharma Gives Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib,2017-11-17 07:06:00-05:00,AGIO,neutral
42513.0,"Agios Pharma Reports Q3 EPS $(1.59) vs $(1.79) Est., Sales $11.358M vs $9.8M Est.",2017-11-01 07:16:00-04:00,AGIO,neutral
42514.0,29 Top Stock Ideas For October And Beyond,2017-10-16 15:29:00-04:00,AGIO,positive
42515.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,AGIO,neutral
42516.0,Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts,2017-09-01 14:03:00-04:00,AGIO,neutral
42517.0,Oppenheimer Presents New Menu Of Top Picks,2017-09-01 11:59:00-04:00,AGIO,positive
42518.0,"Benzinga's Top Upgrades, Downgrades For August 2, 2017",2017-08-02 09:24:00-04:00,AGIO,positive
42519.0,Leerink Swann Upgrades Agios Pharmaceuticals to Outperform,2017-08-02 07:52:00-04:00,AGIO,neutral
42520.0,Meg Tirrell Tweets: SunTrust's Yatin Suneja says Idhifa monthly price is $10K more than he modeled $CELG $AGIO,2017-08-01 13:48:00-04:00,AGIO,neutral
42521.0,Key FDA Events To Watch Out For In August 2017,2017-08-01 12:39:00-04:00,AGIO,neutral
42522.0,FDA Has Approved Idhifa For Treatment Of Adult Patients with Relpased/Refractory AML,2017-08-01 11:00:00-04:00,AGIO,positive
42523.0,Adam Feuerstein Tweets: $CELG $AGIO - FDA approves enasidenib (Idhifa) for r/r AML. Early.,2017-08-01 11:00:00-04:00,AGIO,positive
42524.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,AGIO,neutral
42525.0,Oppenheimer Analysts Release 28 Best Ideas List,2017-06-29 13:24:00-04:00,AGIO,positive
42527.0,12 Biggest Mid-Day Losers For Monday,2017-06-26 13:09:00-04:00,AGIO,negative
42528.0,"Benzinga's Top Upgrades, Downgrades For June 26, 2017",2017-06-26 09:21:00-04:00,AGIO,positive
42529.0,Janney Capital Downgrades Agios Pharmaceuticals to Neutral,2017-06-26 07:47:00-04:00,AGIO,neutral
42530.0,Agios Pharma Announces New Data from Phase 1/2 Trial of Oral IDHIFA Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML #EHA2017,2017-06-24 16:55:00-04:00,AGIO,positive
42531.0,Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as  First Disease-modifying Treatment for Patients with PKR #EHA2017,2017-06-24 16:54:00-04:00,AGIO,neutral
42534.0,"Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data",2017-06-05 13:48:00-04:00,AGIO,neutral
42535.0,Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120  in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma #ASCO17,2017-06-03 09:09:00-04:00,AGIO,positive
42536.0,Thermo Fisher Signs Development Agreement with Agios Pharmaceuticals for Next-Gen Sequencing Oncology Companion Diagnostic in Cholangiocarcinom,2017-05-18 08:05:00-04:00,AGIO,positive
42537.0,"Agios Pharma Q1 EPS $(1.56) vs $(1.71) Est, Sales $10.51M vs $8.07M Est",2017-05-04 09:48:00-04:00,AGIO,neutral
42538.0,"Agios Pharma Reports Entering Into of Exclusive License Deal for Novel Small Molecules for Cancer Metabolism Target, Includes $3M Upfront Payment, Potential Future Milestone Payments for Up to $17M Per Licensed Product",2017-04-27 07:56:00-04:00,AGIO,negative
42539.0,Agios Announces Prices ~5.05M Share Offering of Common Stock @$49.50/Share,2017-04-18 20:36:00-04:00,AGIO,positive
42540.0,Agios Reports Proposed Offering of 4.5M  Shares of Common Stock,2017-04-17 16:01:00-04:00,AGIO,positive
42541.0,"Agios Pharma Reports MTAP Pathway Research Program as Development Program, Development Candidate Under Master Research & Collaboration Deal with Celgene",2017-03-13 07:33:00-04:00,AGIO,neutral
42542.0,Hearing Agios Pharmaceuticals Upgraded To Buy At Janney With PT Of $57,2017-02-16 11:24:00-05:00,AGIO,neutral
42543.0,"Agios Reports Q4 EPS $(1.34) vs. $(1.51) Est., Rev. $22.6M vs. $10.89M Est.",2017-02-16 07:07:00-05:00,AGIO,neutral
42544.0,Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch,2017-01-17 14:42:00-05:00,AGIO,neutral
42545.0,"Benzinga's Top Upgrades, Downgrades For January 17, 2017",2017-01-17 09:22:00-05:00,AGIO,positive
42546.0,Oppenheimer Upgrades Agios Pharmaceuticals to Outperform,2017-01-17 06:17:00-05:00,AGIO,neutral
42547.0,Agios Announces AG-120 NDA Submission for IDH1m R/R AML Planned by Year End 2017,2017-01-09 07:37:00-05:00,AGIO,positive
42548.0,Why The Last Week Of 2016 Could Be Big For Biotech Catalysts,2016-12-27 09:02:00-05:00,AGIO,neutral
42549.0,Agios Pharma Shares Crushed Under Weight Of Clinical Setback,2016-12-16 12:44:00-05:00,AGIO,negative
42550.0,Mid-Morning Market Update: Markets Open Higher; Adobe Beats Q4 Expectations,2016-12-16 09:40:00-05:00,AGIO,neutral
42551.0,15 Stocks Moving In Friday's Pre-Market Session,2016-12-16 08:42:00-05:00,AGIO,neutral
42552.0,"Agios Pharma Shares Resume Trade, Now Down ~17%",2016-12-15 16:31:00-05:00,AGIO,positive
42553.0,Agios Pharma Shares to Resume at 4:30 p.m. EST,2016-12-15 16:25:00-05:00,AGIO,positive
42554.0,"Agios Provides Update on PKR Program, Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback",2016-12-15 16:03:00-05:00,AGIO,neutral
42555.0,"Agios Pharmaceuticals Shares Down 4% MIdday On Above Average Volume; Co Earlier Reported Clinical Data From Phase 1 Trial Of AG-120, Some Investors Showing Safety Concern Over Hepatitis Reported In A Single Patient",2016-12-06 13:26:00-05:00,AGIO,positive
42556.0,Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies at ASH 2016,2016-12-05 19:39:00-05:00,AGIO,positive
42557.0,Mid-Afternoon Market Update: NeuroDerm Surges Following Meeting With FDA; Cerecor Shares Slide,2016-12-05 14:21:00-05:00,AGIO,positive
42558.0,10 Biggest Mid-Day Losers For Monday,2016-12-05 13:01:00-05:00,AGIO,negative
42559.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,AGIO,positive
42560.0,Mid-Day Market Update: NASDAQ Up 1%; Ocean Power Technologies Shares Spike Higher,2016-12-05 12:13:00-05:00,AGIO,positive
42561.0,CNBC's Meg Tirrell Tweets: #ASH16 stocks looking largely opposite of last year. So far: $KITE +9.4% $JUNO +6.6% $ONCE +2.5% On flip side: $GBT -3.3% $AGIO -12%,2016-12-05 10:22:00-05:00,AGIO,neutral
42562.0,Mid-Morning Market Update: Markets Open Higher; Consolidated Communications to Acquire FairPoint Communications,2016-12-05 10:07:00-05:00,AGIO,neutral
42563.0,Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency at ASH 2016,2016-12-05 03:59:00-05:00,AGIO,neutral
42564.0,Oppenheimer Initiates Coverage On Agios Pharmaceuticals at Perform,2016-11-29 08:06:00-05:00,AGIO,neutral
42565.0,"Companies Presenting Data At Society For Neuro-Oncology Meeting Today Include Agios Pharmaceuticals, Celgene, Cellidex Therapeutics, & NewLink Genetics",2016-11-18 08:36:00-05:00,AGIO,neutral
42566.0,Agios Pharma Announces Phase 1 Data  For AG-120,2016-11-18 07:03:00-05:00,AGIO,neutral
42567.0,Agios Reports Q3 EPS $(1.63)  vs. Est. $(1.52),2016-11-03 07:23:00-04:00,AGIO,neutral
42568.0,"Celgene, Agios Report Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML",2016-10-12 07:30:00-04:00,AGIO,positive
42569.0,15 Biggest Mid-Day Gainers For Thursday,2016-09-15 12:44:00-04:00,AGIO,neutral
42570.0,Benzinga's Volume Movers,2016-09-15 11:13:00-04:00,AGIO,neutral
42571.0,"Agios Pharmaceuticals Prices 3,370,786 Shares Offering @ $44.50/Share",2016-09-15 06:35:00-04:00,AGIO,positive
42572.0,12 Biggest Mid-Day Losers For Wednesday,2016-09-14 13:10:00-04:00,AGIO,negative
42573.0,12 Stocks Moving In Wednesday's Pre-Market Session,2016-09-14 08:32:00-04:00,AGIO,neutral
42574.0,Agios Pharmaceuticals To Offer $150M Common Stock,2016-09-13 16:13:00-04:00,AGIO,neutral
42575.0,OptioN Alert: Agios Pharmaceuticals  Nov $50 Calls at the bid: 1823 @ 2.5 vs. Open Interest 1170,2016-09-09 15:09:00-04:00,AGIO,positive
42576.0,Wednesday's Market Wrap: Major Averages Close Mixed,2016-09-07 16:34:00-04:00,AGIO,neutral
42577.0,18 Biggest Mid-Day Gainers For Wednesday,2016-09-07 12:58:00-04:00,AGIO,neutral
42578.0,Mid-Day Market Update: Sprouts Farmers Market Drops Following Guidance Cut; Cogentix Medical Shares Surge,2016-09-07 12:10:00-04:00,AGIO,neutral
42579.0,Benzinga's Volume Movers,2016-09-07 10:44:00-04:00,AGIO,neutral
42580.0,Mid-Morning Market Update: Markets Mostly Flat; HD Supply Misses Q2 Views,2016-09-07 10:13:00-04:00,AGIO,negative
42581.0,22 Stocks Moving In Wednesday's Pre-Market Session,2016-09-07 08:28:00-04:00,AGIO,neutral
42582.0,"Celgene, Agios To Submit NDA For enasidenib Based On Ongoing Phase 1/2 Study",2016-09-07 08:07:00-04:00,AGIO,neutral
42583.0,Option Alert: Agios Pharmaceuticals Feb 17 $50 Calls Sweep at the ask: 1000 @ 3.8 vs. Open Interest 137; Ref=$37.20,2016-08-30 13:50:00-04:00,AGIO,positive
42584.0,Why This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates,2016-08-19 11:59:00-04:00,AGIO,neutral
42585.0,BTIG Research Initiates Coverage on Agios Pharmaceuticals at Neutral,2016-08-19 07:57:00-04:00,AGIO,neutral
42586.0,Agios Names Andrew Hirsch CFO,2016-08-16 07:33:00-04:00,AGIO,neutral
42587.0,Q2 Earnings Report Card: Biotech,2016-08-08 13:31:00-04:00,AGIO,neutral
42588.0,"Agios Pharmaceuticals Reports Q2 EPS $(1.47) vs. Est. $(0.48), Rev. $6.9M",2016-08-04 07:37:00-04:00,AGIO,neutral
42589.0,"Canaccord Sees $40 In Upside For Agios, Upgrades To Buy",2016-06-13 11:09:00-04:00,AGIO,neutral
42590.0,JPMorgan Upgrades Agios Pharma To Overweight Despite Last Week's 25% Decline,2016-06-13 10:28:00-04:00,AGIO,negative
42591.0,6 Largest Price Target Changes For Monday,2016-06-13 09:32:00-04:00,AGIO,neutral
42592.0,"The Market In 5 Minutes: Microsoft-LinkedIn, And Some Major iPhone News",2016-06-13 09:07:00-04:00,AGIO,neutral
42593.0,Goldman Sachs: 3 Questions For Agios Pharmaceuticals,2016-06-13 08:56:00-04:00,AGIO,neutral
42594.0,10 Stocks Moving In Monday's Pre-Market Session,2016-06-13 08:25:00-04:00,AGIO,neutral
42595.0,Canaccord Genuity Upgrades Agios Pharmaceuticals to Buy,2016-06-13 06:09:00-04:00,AGIO,neutral
42596.0,"Agios Pharmaceuticals Upgraded From Neutral To Overweight AT JP Morgan, PT Raised From $50 to $62",2016-06-13 03:36:00-04:00,AGIO,neutral
42597.0,Agios Announces AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency,2016-06-11 08:36:00-04:00,AGIO,neutral
42598.0,Option Alert: SWEEP (SELL) - AGIO June $50 Call- 2000 @ 6.3 in 3 orders. 2000 traded. OI: 959,2016-06-10 10:14:00-04:00,AGIO,positive
42599.0,11 Biggest Mid-Day Losers For Thursday,2016-06-09 12:52:00-04:00,AGIO,negative
42600.0,"Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers, Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing",2016-06-09 09:22:00-04:00,AGIO,positive
42601.0,Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of EHA,2016-05-19 07:09:00-04:00,AGIO,neutral
42602.0,"UPDATE: Agios Pro-Forma Cash Balance as of Mar. 31, 2016 $556M",2016-05-17 16:04:00-04:00,AGIO,neutral
42603.0,Agios Sees FY16 Ending Cash Position of $390M+,2016-05-17 16:03:00-04:00,AGIO,neutral
42604.0,"UPDATE: Agios Will Receive Upfront Cash Payment of $200M Plus Potential for Added Payments if Certain Development, Regulatory Milestones Achieved",2016-05-17 16:02:00-04:00,AGIO,positive
42605.0,Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement,2016-05-17 16:02:00-04:00,AGIO,positive
42606.0,"Agios, Celgene Report New Collab in Metabolic Immuno-Oncology, Amend Certain Rights from '10 Deal",2016-05-17 16:01:00-04:00,AGIO,positive
42607.0,"Agios Reports Q1 EPS $(0.61) vs. Est. $(0.79), Rev. $31.281M vs. Est. $20.94M",2016-05-05 07:39:00-04:00,AGIO,neutral
42608.0,Benzinga's Top Initiations,2016-03-30 09:14:00-04:00,AGIO,positive
42609.0,Agios Initiates Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy,2016-03-30 07:03:00-04:00,AGIO,neutral
42610.0,"SunTrust Robinson Humphrey Initiates Coverage on Agios Pharmaceuticals at Buy, Announces $57.00 PT",2016-03-30 06:30:00-04:00,AGIO,neutral
42611.0,23 Ways To Say 'I'm A Contrarian Investor',2016-03-24 11:49:00-04:00,AGIO,neutral
42612.0,Benzinga's Top Initiations,2016-03-02 09:45:00-05:00,AGIO,positive
42613.0,Janney Capital Initiates Coverage on Agios Pharmaceuticals at Neutral,2016-03-02 06:38:00-05:00,AGIO,neutral
42614.0,Agios Reports Q4 EPS $(1.08) vs. Est. $(0.50),2016-02-18 07:06:00-05:00,AGIO,neutral
42615.0,"Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks",2016-01-21 12:16:00-05:00,AGIO,positive
42616.0,"Credit Suisse Initiates Coverage on Agios Pharmaceuticals at Outperform, Announces $75.00 PT",2016-01-20 16:46:00-05:00,AGIO,positive
42617.0,Agios Announces Starts of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients,2015-12-18 07:30:00-05:00,AGIO,neutral
42618.0,Stocks Hitting 52-Week Lows,2015-12-07 10:19:00-05:00,AGIO,negative
42619.0,Mid-Morning Market Update: Markets Open Lower; Keurig Green Mountain Agrees To Be Taken Private For $92/Share,2015-12-07 10:03:00-05:00,AGIO,negative
42620.0,Morning Market Losers,2015-12-07 09:53:00-05:00,AGIO,negative
42621.0,Leerink Swann Downgrades Agios Pharmaceuticals to Market Perform,2015-12-07 07:55:00-05:00,AGIO,neutral
42622.0,Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies at #ASH2015,2015-12-06 18:59:00-05:00,AGIO,positive
42623.0,Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies at #ASH15,2015-12-05 10:22:00-05:00,AGIO,positive
42624.0,Agios Announces Safety Profile Confirmed in Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors,2015-11-08 08:27:00-05:00,AGIO,positive
42625.0,"Agios Reports Q3 EPS $(1.07) vs. Est. $(0.88), Rev. $5.48M vs. Est. $17.21M",2015-11-05 07:02:00-05:00,AGIO,neutral
42626.0,Agios to Show Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC,2015-10-26 16:40:00-04:00,AGIO,positive
42628.0,Here's Why Biotechs Fell On Monday,2015-10-19 16:29:00-04:00,AGIO,neutral
42629.0,Canaccord's Newman Cuts Agios Pharma Price Target from $93 to $70; Warns of 'Cautious AG-120 solid tumor commentary at analyst day',2015-10-19 09:09:00-04:00,AGIO,negative
42630.0,"UPDATE: Agios Reports Frontline Combo Development Strategy for AG-221, AG-120",2015-10-16 07:03:00-04:00,AGIO,neutral
42631.0,Agios Pharma Reports Phase 3 Study of AG-221 in IDH2 Leukemia Initiated,2015-10-16 07:02:00-04:00,AGIO,neutral
42632.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,AGIO,neutral
42633.0,"In new note to subscribers, CMT Christian Tharp making bet that 15-20% correction is coming",2015-08-21 15:39:00-04:00,AGIO,neutral
42634.0,"Northland Securities Initiates Coverage on Agios Pharmaceuticals at Outperform, Announces $132.00 PT",2015-07-22 08:41:00-04:00,AGIO,positive
42635.0,Agios Reports First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation,2015-06-24 07:31:00-04:00,AGIO,positive
42636.0,Agios Appoints Maykin Ho To Board of Directors,2015-06-23 16:04:00-04:00,AGIO,neutral
42637.0,Agios Pharma Dip Below $100 Level as Hearing Canaccord Analyst Offers Warning,2015-06-15 10:42:00-04:00,AGIO,negative
42638.0,"Roth Capital's Chattopadhyay Believes Agios Pharma's AG-221 'Continues to be Compelling,' Maintains Neutral, $114 Target",2015-06-15 06:41:00-04:00,AGIO,neutral
42639.0,Mid-Afternoon Market Update: Wingstop Shares Surge in Stock Market Debut; ExOne Shares Tumble,2015-06-12 15:17:00-04:00,AGIO,positive
42640.0,Mid-Day Market Update: Restoration Hardware Rises On Earnings Beat; Agios Pharmaceuticals Shares Slide,2015-06-12 12:54:00-04:00,AGIO,positive
42641.0,Mid-Morning Market Update: Markets Open Lower; Twitter CEO Dick Costolo Resigns,2015-06-12 12:05:00-04:00,AGIO,negative
42642.0,Morning Market Losers,2015-06-12 10:00:00-04:00,AGIO,negative
42643.0,Benzinga's Top #PreMarket Gainers,2015-06-12 08:20:00-04:00,AGIO,positive
42644.0,US Stock Futures Slide Ahead Of Economic Data,2015-06-12 07:22:00-04:00,AGIO,neutral
42645.0,"Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency",2015-06-12 06:03:00-04:00,AGIO,positive
42646.0,Agios Pharmaceuticals Reports FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia,2015-06-10 16:40:00-04:00,AGIO,positive
42647.0,Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation,2015-05-18 07:31:00-04:00,AGIO,positive
42648.0,Agios Pharma Updates Late-Stage Clinical Development For AG-221 & AG-120,2015-05-07 07:38:00-04:00,AGIO,neutral
42649.0,"Agios Reports Q1 EPS $(0.13) vs. Est. $(0.92), Rev. $34.2M vs. Est. $10.86M; Estimates May Not Be Comparable",2015-05-07 07:36:00-04:00,AGIO,neutral
42650.0,Investing In Personalized Cancer Treatment,2015-05-06 13:57:00-04:00,AGIO,negative
42651.0,"Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestle Health Science and Bayer CropScience",2015-05-05 07:17:00-04:00,AGIO,positive
42652.0,Canaccord Downgrading Agios To Hold,2015-04-30 12:26:00-04:00,AGIO,neutral
42653.0,"Canaccord Genuity Downgrades Agios Pharmaceuticals to Hold, Lowers PT to $103.00",2015-04-30 05:10:00-04:00,AGIO,negative
42654.0,"Agios Pharmaceuticals Chooses Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development",2015-04-29 07:01:00-04:00,AGIO,positive
42655.0,Oppenheimer Initiates Coverage on Agios Pharmaceuticals at Perform,2015-04-20 16:53:00-04:00,AGIO,neutral
42656.0,Agios Pharmaceuticals Has Been Plummeting,2015-03-26 08:09:00-04:00,AGIO,neutral
42657.0,UPDATE: Agios Plans TO Initiate A Phase 2 Clincical Trial In Hq of 2015,2015-03-24 15:07:00-04:00,AGIO,neutral
42658.0,Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency,2015-03-24 15:05:00-04:00,AGIO,neutral
42659.0,Morning Market Losers,2015-02-17 09:53:00-05:00,AGIO,negative
42660.0,Agios Pharma Shares Fall 5.5% Premarket Following Wider than Expected Loss,2015-02-17 09:12:00-05:00,AGIO,neutral
42661.0,"Agios Pharma Reports EPS Loss $0.76 Vs Est Loss $0.58, Sales $14.6M Vs Est $10.94M",2015-02-17 07:34:00-05:00,AGIO,negative
42662.0,"Earnings Scheduled For February 17, 2015",2015-02-17 04:46:00-05:00,AGIO,neutral
42663.0,UPDATE: Citigroup Downgrades Agios Pharmaceuticals As Valuation Is Stretched,2015-01-28 08:43:00-05:00,AGIO,neutral
42664.0,Benzinga's Top #PreMarket Losers,2015-01-28 08:19:00-05:00,AGIO,negative
42665.0,Citigroup Downgrades Agios Pharmaceuticals to Neutral,2015-01-28 07:57:00-05:00,AGIO,neutral
42666.0,Agios Announces That Celgene Has Agreed To Exercise Its Option To License AG-120 Under Global Strategic Collaboration,2015-01-12 16:08:00-05:00,AGIO,positive
42667.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,AGIO,neutral
42668.0,The Top 5 Biotech Gainers Of 2014,2014-12-29 14:15:00-05:00,AGIO,positive
42669.0,"Biotech Stocks Sell Off, ETFs Fall Over 5%",2014-12-23 14:35:00-05:00,AGIO,neutral
42670.0,CNBC's Stock Pops & Drops From December 11,2014-12-12 07:19:00-05:00,AGIO,neutral
42671.0,Agios Pharmaceuticals Prices ~1.986M Share Offering @$110.75/Share,2014-12-10 20:43:00-05:00,AGIO,positive
42672.0,Agios Press Release Confirms Offering of Up to $175M in Common Shares,2014-12-09 16:22:00-05:00,AGIO,positive
42673.0,Filing from Agios Pharma Shows Registration for Automatic Mixed Securities Shelf Offering,2014-12-09 16:10:00-05:00,AGIO,positive
42674.0,These 4 Biotech Stocks Have Been On Fire,2014-12-08 15:31:00-05:00,AGIO,negative
42675.0,Agios Reports Positive Phase 1 Data In Healthy Volunteers For AG-348,2014-12-08 13:00:00-05:00,AGIO,positive
42676.0,Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For $102/Share,2014-12-08 10:46:00-05:00,AGIO,neutral
42677.0,Morning Market Movers,2014-12-08 09:44:00-05:00,AGIO,neutral
42678.0,"Celgene Shares Rise 2% Premarket Following ASH Presentations, Extension of Collaboration with Agios",2014-12-08 08:26:00-05:00,AGIO,positive
42679.0,Benzinga's Top #PreMarket Gainers,2014-12-08 08:11:00-05:00,AGIO,positive
42680.0,Agios Pharma Reports Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to Apr. '16,2014-12-08 07:32:00-05:00,AGIO,positive
42681.0,Agios Announces Positive Data from Ongoing Phase 1 Trial of AG-221 at ASH Annual Meeting,2014-12-07 16:17:00-05:00,AGIO,positive
42682.0,UPDATE: MLV Initiates Coverage On Agios Pharmaceuticals,2014-12-04 10:22:00-05:00,AGIO,neutral
42683.0,"MLV & Co. Initiates Coverage on Agios Pharmaceuticals at Buy, Announces $123.00 PT",2014-12-04 07:51:00-05:00,AGIO,neutral
42684.0,"JP Morgan Downgrades Agios Pharmaceuticals to Neutral, Raises PT to $90.00",2014-12-02 06:25:00-05:00,AGIO,positive
42685.0,Could This Biotech Stock Fall Even Further?,2014-12-01 17:16:00-05:00,AGIO,neutral
42686.0,CNBC's Stock Pops & Drops From November 19,2014-11-20 07:38:00-05:00,AGIO,neutral
42687.0,"Mid-Day Gainers From November 19: Stage Stores, China Distance Education, Oplink, Agios Pharmaceuticals, Staples",2014-11-19 12:13:00-05:00,AGIO,neutral
42688.0,Benzinga's Volume Movers,2014-11-19 10:31:00-05:00,AGIO,neutral
42689.0,UPDATE: Agios Pharmaceuticals Announces Positive Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in AML,2014-11-18 18:08:00-05:00,AGIO,positive
42690.0,Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia,2014-11-18 18:07:00-05:00,AGIO,positive
42691.0,"Canaccord Genuity Initiates Coverage on Agios Pharmaceuticals at Buy, Announces $97.00 PT",2014-11-12 06:22:00-05:00,AGIO,neutral
42692.0,"Citigroup Maintains Hold on Agios Pharmaceuticals, Raises PT to $93.00",2014-11-10 08:48:00-05:00,AGIO,neutral
42693.0,"Earnings Scheduled For November 7, 2014",2014-11-07 05:13:00-05:00,AGIO,neutral
42694.0,"Midday Gainers From October 21: Aircastle, American Airlines, Agios Pharmaceuticals",2014-10-21 13:44:00-04:00,AGIO,neutral
42695.0,Agios Pharma Reports Initiation of Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with IDH2 Mutation,2014-10-21 08:31:00-04:00,AGIO,positive
42696.0,Agios Pharmaceuticals Announces Initiation Of Four Expansion Cohorts In Phase 1 Study Of AG-221,2014-10-15 07:32:00-04:00,AGIO,neutral
42697.0,"Agios Pharmaceuticals Inc, Altria Group Inc Highlight CNBC's Stock Pops & Drops From September 26",2014-09-27 10:33:00-04:00,AGIO,positive
42698.0,Benzinga's Volume Movers,2014-09-26 10:14:00-04:00,AGIO,neutral
42699.0,Shares of Agios Pharma Getting a Cramer Pop Right Now -- He Just Mentioned on CNBC,2014-09-26 09:57:00-04:00,AGIO,positive
42700.0,Agios Pharmaceuticals Share Spike Higher; Positive Jim Cramer/CNBC Comments,2014-09-26 09:57:00-04:00,AGIO,positive
42701.0,Agios Pharmaceuticals To Present Clinical Data From AG-120 Ongoing Phase 1 Study In Hematologic Malignancies At EORTC-NCI-AACR 2014,2014-09-26 07:32:00-04:00,AGIO,neutral
42702.0,Benzinga's Volume Movers,2014-09-17 10:17:00-04:00,AGIO,neutral
42703.0,Morning Market Movers ,2014-09-17 09:38:00-04:00,AGIO,neutral
42704.0,Benzinga's Top #PreMarket Gainers,2014-09-17 08:08:00-04:00,AGIO,positive
42705.0,Shares of Agios Pharmaceuticals Rise 10% After-Hours on Positive Jim Cramer/Mad Money Comments,2014-09-16 18:57:00-04:00,AGIO,positive
42706.0,Agios Pharma Announces Fast Track Designation For AG-221,2014-08-13 08:31:00-04:00,AGIO,neutral
42707.0,Agios Pharmaceuticals Reports Q2 EPS of $(0.54) vs $(0.41) Est,2014-08-07 07:35:00-04:00,AGIO,neutral
42708.0,"Citigroup Initiates Coverage on Agios Pharmaceuticals at Buy, Announces $58.00 PT",2014-07-01 08:17:00-04:00,AGIO,neutral
42709.0,"Agios Pharmaceuticals Directr Maraganore Buys 2,300 Shares @$43.98/Share -Form 4",2014-06-24 08:22:00-04:00,AGIO,positive
42710.0,"Mid-Day Market Movers For Monday, June 23, 2014",2014-06-23 15:43:00-04:00,AGIO,neutral
42711.0,Agios Recieves Orphan Designation for AG-221,2014-06-16 08:02:00-04:00,AGIO,neutral
42712.0,Agios Presents Positive Clinical Data from Ongoing Phase 1 Trial of AG-221 in Patients with Hematologic Malignancies at EHA ,2014-06-14 09:30:00-04:00,AGIO,positive
42713.0,Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th,2014-06-10 11:04:00-04:00,AGIO,neutral
42714.0,Agios Pharmaceuticals to Present New Clinical Data from AG-221 Ongoing Phase 1 Study at the 19th Congress of EHA,2014-05-22 05:41:00-04:00,AGIO,neutral
42715.0,"Agios Pharmaceuticals Names Chris Bowden, M.D., as Chief Medical Officer ",2014-05-14 08:34:00-04:00,AGIO,neutral
42716.0,Agios Pharmaceuticals Reports Q1 EPS of $(0.39) vs $(0.38) Est; Revenue of $8.41M vs $7.30M Est,2014-05-08 07:37:00-04:00,AGIO,neutral
42717.0,Agios Pharma Announces Public Offering of 2M Shares,2014-04-21 16:01:00-04:00,AGIO,positive
42718.0,Agios Initiates Phase 1 Study of AG-348,2014-04-17 08:00:00-04:00,AGIO,neutral
42719.0,Market Wrap For April 7: Bears In Complete Control As Markets Get Hammered Yet Again,2014-04-07 16:41:00-04:00,AGIO,neutral
42720.0,Mid-Afternoon Market Update: Markets Continue to Show Weakness as Defensive Names Come into Favor,2014-04-07 15:46:00-04:00,AGIO,neutral
42721.0,Mid-Day Market Update: Dow Tumbles Over 100 Points; Intel Shares Rise Following Analyst Upgrade,2014-04-07 12:35:00-04:00,AGIO,positive
42722.0,Benzinga's Volume Movers,2014-04-07 10:47:00-04:00,AGIO,neutral
42723.0,Mid-Morning Market Update: Markets Drop; Mallinckrodt To Acquire Questcor Pharmaceuticals For $5.6B,2014-04-07 10:32:00-04:00,AGIO,negative
42724.0,Morning Market Movers ,2014-04-07 09:40:00-04:00,AGIO,neutral
42725.0,Benzinga's Top #PreMarket Gainers,2014-04-07 08:28:00-04:00,AGIO,positive
42726.0,"JP Morgan Upgrades Agios Pharmaceuticals to Overweight, Raises PT to $55.00",2014-04-07 08:08:00-04:00,AGIO,neutral
42727.0,Agios Announces Initial Phase 1 AG-221 Data Presented at AACR 2014,2014-04-06 19:37:00-04:00,AGIO,neutral
42728.0,Agios First Patient Enrolled in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation ,2014-03-19 08:04:00-04:00,AGIO,positive
42729.0,"Mid-Afternoon Market Update: Markets Turn Up From the Lows, Fuel Cell Companies Show Weakness",2014-03-06 15:52:00-05:00,AGIO,negative
42730.0,Mid-Day Market Update: Costco Shares Decline After Weak Quarterly Results; Stage Stores Spikes Higher,2014-03-06 12:28:00-05:00,AGIO,negative
42731.0,Mid-Morning Market Update: Markets Open Higher; Staples Plans To Close 225 Stores,2014-03-06 10:21:00-05:00,AGIO,neutral
42732.0,Agios Presents Preclinical Data from Lead Programs at ASH,2013-12-09 21:00:00-05:00,AGIO,neutral
42733.0,Stocks Hitting 52-Week Lows,2013-11-15 11:26:00-05:00,AGIO,negative
42734.0,Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221,2013-09-23 06:44:00-04:00,AGIO,neutral
42735.0,UPDATE: Goldman Sachs Initiates Agios Pharmaceuticals with Buy on Emerging Leadership Position,2013-08-19 10:21:00-04:00,AGIO,neutral
42736.0,"JP Morgan Initiates Coverage on Agios Pharmaceuticals at Neutral, Announces $35.00 PT",2013-08-19 08:20:00-04:00,AGIO,positive
42737.0,"Leerink Swann Initiates Coverage on Agios Pharmaceuticals at Outperform, Announces $38.00 PT",2013-08-19 08:20:00-04:00,AGIO,neutral
42738.0,Cowen & Company Initiates Coverage on Agios Pharmaceuticals at Outperform,2013-08-19 08:19:00-04:00,AGIO,neutral
42739.0,Benzinga's Top Initiations,2013-08-19 07:46:00-04:00,AGIO,positive
42740.0,"Goldman Sachs Initiates Coverage on Agios Pharmaceuticals at Buy, Announces $37.00 PT",2013-08-19 07:28:00-04:00,AGIO,neutral
42741.0,"Agios Pharmaceuticals Closes Initial Public Offering, Underwriters Exercised Full Option",2013-07-29 17:03:00-04:00,AGIO,neutral
42742.0,Mid-Afternoon Market Update: Agios Pharma Has Wildly Successful IPO Amid Red Markets,2013-07-24 15:43:00-04:00,AGIO,positive
42743.0,"Shares of Agios Pharma Opens for Trade at $29, Priced at $18/Share",2013-07-24 11:00:00-04:00,AGIO,positive
42744.0,"Shares of Agios Pharma to Open for Quote at 10:25AM EDT, Expected to Open for Trade at 10:40AM; Priced 5.88M Shares at $18/Share",2013-07-24 10:07:00-04:00,AGIO,positive
42745.0,Agios Pharmaceuticals Prices 5.9M Share IPO at $18.00/Share,2013-07-24 06:59:00-04:00,AGIO,positive
42746.0,"Agios Pharma to Offer 5M Shares in $14-16/Share Range in IPO, Will List on NASDAQ",2013-07-16 17:18:00-04:00,AGIO,positive
